Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymalfasin alpha-1 plus raltitrexed in advanced colorectal cancer
ChiCTR-IIR-17013316Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Nov 2017
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thymosin alpha 1 and raltitrexed in colorectal cancer (CRC) (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: overall survival. Started Nov 2017; status: recruiting.
02
Drugs
thymosin alpha 1raltitrexed
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-IIR-17013316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013316.